ABSTRACT
The Marburg virus (MARV), an African filovirus closely related to the Ebola virus, causes a deadly hemorrhagic fever in humans, with up to 90% mortality. Currently, treatment of disease is only supportive, and no vaccines are available to prevent spread of MARV infections. In order to address this need, we have developed and characterized a novel recombinant vaccine that utilizes a single complex adenovirus-vectored vaccine (cAdVax) to overexpress a MARV glycoprotein (GP) fusion protein derived from the Musoke and Ci67 strains of MARV. Vaccination with the cAdVaxM(fus) vaccine led to efficient production of MARV-specific antibodies in both mice and guinea pigs. Significantly, guinea pigs vaccinated with at least 5 x 10(7) pfu of cAdVaxM(fus) vaccine were 100% protected against lethal challenges by the Musoke, Ci67 and Ravn strains of MARV, making it a vaccine with trivalent protective efficacy. Therefore, the cAdVaxM(fus) vaccine serves as a promising vaccine candidate to prevent and contain multi-strain infections by MARV.
Subject(s)
Adenoviridae/metabolism , Antigens, Viral/biosynthesis , Ebola Vaccines/administration & dosage , Genetic Vectors/metabolism , Marburg Virus Disease/prevention & control , Marburgvirus/immunology , Vaccination , Viral Envelope Proteins/biosynthesis , Viral Fusion Proteins/biosynthesis , Adenoviridae/genetics , Amino Acid Sequence , Animals , Antibodies, Viral/blood , Antigens, Viral/genetics , Cell Line , Chlorocebus aethiops , Dose-Response Relationship, Immunologic , Ebola Vaccines/genetics , Genetic Therapy/methods , Guinea Pigs , Humans , Injections, Intraperitoneal , Injections, Subcutaneous , Marburg Virus Disease/blood , Marburg Virus Disease/immunology , Mice , Molecular Sequence Data , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Sequence Alignment , Vaccines, Synthetic/administration & dosage , Viral Envelope Proteins/genetics , Viral Fusion Proteins/geneticsABSTRACT
Marburg virus (MARV) is an African filovirus that causes a deadly hemorrhagic fever in humans, with up to 90% mortality. Currently, there are no MARV vaccines or therapies approved for human use. We hypothesized that developing a vaccine that induces a de novo synthesis of MARV antigens in vivo will lead to strong induction of both a humoral and cell-mediated immune response against MARV. Here, we develop and characterize three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV. Immunization of mice with complex adenovirus (Ad)-based vaccine candidates (cAdVax vaccines), led to efficient production of both antibodies and cytotoxic T lymphocytes (CTL) specific to Musoke strain GP and Ci67 strain GP, respectively. Antibody responses were also shown to be cross-reactive across the MARV strains, but not cross-reactive to Ebola virus, a related filovirus. Additionally, three 1 x 10(8)pfu doses of vaccine vector were demonstrated to be safe in mice, as this did not lead to any detectable toxicity in liver or spleen. These promising results indicate that a cAdVax-based vaccine could be effective for induction of both humoral and cell-mediated immune responses to multiple strains of the Marburg virus.
Subject(s)
Adenoviridae/genetics , Marburg Virus Disease/prevention & control , Marburgvirus/genetics , Viral Envelope Proteins/immunology , Viral Vaccines/immunology , Animals , Antibodies, Viral/blood , Antigens, Viral/biosynthesis , Antigens, Viral/genetics , Antigens, Viral/immunology , Cross Reactions , Cytotoxicity Tests, Immunologic , Enzyme-Linked Immunosorbent Assay , Genetic Vectors , Humans , Liver/pathology , Marburg Virus Disease/immunology , Marburgvirus/immunology , Mice , Mice, Inbred C57BL , Models, Animal , Spleen/pathology , T-Lymphocytes, Cytotoxic/immunology , Viral Envelope Proteins/biosynthesis , Viral Envelope Proteins/genetics , Viral Vaccines/administration & dosage , Viral Vaccines/adverse effects , Viral Vaccines/geneticsABSTRACT
Ebola virus (EBOV) causes a severe hemorrhagic fever for which there are currently no vaccines or effective treatments. While lethal human outbreaks have so far been restricted to sub-Saharan Africa, the potential exploitation of EBOV as a biological weapon cannot be ignored. Two species of EBOV, Sudan ebolavirus (SEBOV) and Zaire ebolavirus (ZEBOV), have been responsible for all of the deadly human outbreaks resulting from this virus. Therefore, it is important to develop a vaccine that can prevent infection by both lethal species. Here, we describe the bivalent cAdVaxE(GPs/z) vaccine, which includes the SEBOV glycoprotein (GP) and ZEBOV GP genes together in a single complex adenovirus-based vaccine (cAdVax) vector. Vaccination of mice with the bivalent cAdVaxE(GPs/z) vaccine led to efficient induction of EBOV-specific antibody and cell-mediated immune responses to both species of EBOV. In addition, the cAdVax technology demonstrated induction of a 100% protective immune response in mice, as all vaccinated C57BL/6 and BALB/c mice survived challenge with a lethal dose of ZEBOV (30,000 times the 50% lethal dose). This study demonstrates the potential efficacy of a bivalent EBOV vaccine based on a cAdVax vaccine vector design.